JOHNSON & JOHNSONJNJ
JOHNSON & JOHNSON Financial Overview 2022–2025
Updated Jul 10, 2026Johnson & Johnson’s earnings before taxes more than doubled to $32.6 billion in FY2025, driven by a massive $7.0 billion reversal of a talc litigation reserve. Beyond the courtroom math, the underlying investment thesis is clear: the company is successfully insulating its top line from severe patent cliffs by aggressively acquiring MedTech growth engines and leaning into high-growth oncology treatments.
Despite spinning off its consumer health unit in 2023, worldwide sales grew from $93.8 billion in FY2021 to $94.2 billion in FY2025. This revenue resilience relies heavily on acquired assets offsetting legacy declines. While biosimilar competition crushed STELARA sales by 41.3% in FY2025, the MedTech segment's cardiovascular franchise surged 15.8% following the integrations of Abiomed and Shockwave Medical. Oncology products like DARZALEX further anchored the Innovative Medicine segment, pushing total top-line growth to 9.9% in Q1 2026 and generating $24.1 billion in a single quarter.
The company’s capital return strategy remains largely untouched by its ongoing restructuring and legal maneuvering. Management raised the dividend for the 64th consecutive year to an annualized $5.36 per share in Q1 2026, even as net debt expanded to $27.8 billion in FY2025 to fund pipeline buyouts. The market priced in this operational durability at the close of FY2025, when the stock traded at 18.8x earnings at a price of $207.63 per share.
Recent Developments (Q4 2025 and Q1 2026)
Johnson & Johnson aims to streamline operations by separating its Orthopaedics business within 18-24 months, a strategic pivot announced following Q4 2025. During Q1 2026, segment-level performance remained solid. Innovative Medicine sales climbed 11.2% to $15.4 billion, and MedTech rose 7.7% to $8.6 billion. However, net earnings for Q1 2026 plunged to $5.2 billion from $11.0 billion in Q1 2025, primarily due to the absence of prior reserve reversals, even as the effective tax rate dropped to 12.6%.
The pipeline also expanded via the strategic buyout of CAPLYTA. Bulls argue that shedding slower-growth orthopaedics will permanently lift operating margins and amplify high-growth therapies. Bears caution that steep net earnings declines expose the underlying cost of corporate restructuring and a heavy reliance on one-off tax benefits. Investors priced the stock at 20.5x earnings at a share price of $226.10 as of April 2026.
What to watch: progress on the Orthopaedics separation timeline; margin impacts from the CAPLYTA acquisition
Rev
$94.19B
FY2025
NI
$26.80B
FY2025
EPS
$11.13
FY2025
OCF
$24.53B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
All JNJ Financial Metrics(59)
Income Statement
Balance Sheet
- Cash & ST Investments
- Total Assets
- Current Assets
- Cash
- Short-Term Investments
- Receivables
- Inventory
- Prepaid & Other
- PP&E
- Goodwill
- Intangibles
- Other Non-current
- Total Liabilities
- Current Liabilities
- Accounts Payable
- Accrued Liabilities
- Short-Term Debt
- Long-Term Debt
- Other Non-current Liab.
- Equity
- Retained Earnings
- Accumulated OCI
- Treasury Stock
- NCI
- Total L&E
Cash Flow
Recent SEC Filings
JOHNSON & JOHNSON 8-K Report, Executive Changes (Aug 4, 2026)
Johnson & Johnson (JNJ) has filed an 8-K reporting a significant leadership transition. Effective September 1, 2026, Jennifer Taubert will retire from her role as Executive Vice President, Worldwide Chairman of Innovative Medicine and as a member of the Executive Committee. This departure marks the end of Ms. Taubert's tenure in a crucial leadership position overseeing the company's pharmaceutical segment. While the filing itself is brief and primarily announces the retirement, investors should note that the company has attached a press release (Exhibit 99.1) providing further details. The announcement signals a change at the highest levels of the Innovative Medicine business, and the market will likely look to future communications from Johnson & Johnson for information regarding succession plans and the strategic direction of this key segment under new leadership. Investors are advised to review the accompanying press release for a more comprehensive understanding of the transition and its potential implications.
JOHNSON & JOHNSON 8-K Report, Regulation FD Disclosure (Jul 29, 2026)
Johnson & Johnson (JNJ) announced on July 29, 2026, the completion of its acquisition of Firefly Bio, Inc. and the initiation of strategic agreements and collaboration with Sail Biomedicines. These transactions are expected to have a significant near-term impact on the Company's earnings. Specifically, JNJ anticipates a reduction in its 2026 Adjusted Operational EPS and Adjusted EPS by approximately $0.64 per share. This impact is split between the Firefly acquisition ($0.46) and the Sail collaboration ($0.18). As a result of these moves, Johnson & Johnson is revising its full-year 2026 financial guidance. The most notable adjustment is a decrease in the midpoint of its Adjusted Operational EPS guidance to $10.94 from $11.58 and its Adjusted EPS guidance to $11.04 from $11.68. This guidance revision reflects a decrease of $0.64 in both measures, indicating a shift in profitability expectations for the current fiscal year. The company also projects a reduction in its adjusted pre-tax operating margin by approximately 150 basis points compared to the prior year.
JOHNSON & JOHNSON 8-K Report, Regulation FD Disclosure (Jul 28, 2026)
Johnson & Johnson announced on July 27, 2026, a significant development concerning its talc litigation. The company has reached an agreement for a comprehensive resolution of ovarian talc litigation, subject to a high participation rate of 95% of remaining claims. This agreement represents a material step towards resolving a long-standing legal overhang for the company. The proposed resolution includes a total commitment of $5.5 billion from Johnson & Johnson. The payment structure is designed to manage cash flow, with an initial payment of no more than $3 billion expected in 2027 and no further payments due before 2028. This strategic move aims to provide clarity and potentially reduce future legal uncertainties, allowing the company to focus on its core operations and growth strategies.
JOHNSON & JOHNSON 8-K Report, Financial Results (Jul 15, 2026)
Johnson & Johnson announced its second-quarter financial results for the period ended June 28, 2026, via a press release filed on July 15, 2026. This 8-K filing primarily serves to furnish the details of this earnings announcement to the SEC, providing investors with key operational and financial data. Investors should review the attached press release (Exhibit 99.1) and supplementary sales data (Exhibit 99.2) for a comprehensive understanding of the Company's performance during the quarter.
JOHNSON & JOHNSON 8-K Report, Shareholder Vote Results (Apr 28, 2026)
Johnson & Johnson (JNJ) filed an 8-K on April 28, 2026, detailing the outcomes of its 2026 Annual Meeting of Shareholders held on April 23, 2026. The report indicates strong shareholder support for the company's slate of director nominees and its executive compensation practices. All 12 director nominees were elected to the Board of Directors, and the executive compensation, as described in the proxy statement, was approved on an advisory basis. Additionally, shareholders ratified the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for fiscal year 2026, reflecting confidence in the company's governance and financial oversight. Notably, a shareholder proposal seeking to adopt a policy requiring an independent board chair was not approved. This outcome suggests that the current board structure and leadership model are favored by the majority of JNJ's shareholders. The detailed voting results for each item are provided in the filing, offering transparency into shareholder sentiment on key governance matters.
View all 8-K filings →